Abstract
The pathophysiology of stroke in humans is much more complex than what is typically studied in animal models. Embolic stroke models are more complex than pure ischemia models, but are more representative of human disease and may be particularly useful in the study of new therapeutic strategies. Vascular damage is a prominent feature of embolic stroke, and may be a useful therapeutic target. Serotonin antagonists, adenosine-regulating agents, free radical scavengers, matrix metalloproteinase inhibitors, and HMG-CoA reductase inhibitors are all potentially valuable agents in treating vascular damage after stroke. These agents facilitate decreased infarction volume, hemorrhage, and improved cerebral blood flow.
| Original language | English |
|---|---|
| Pages (from-to) | 896-904 |
| Number of pages | 9 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 3 |
| Issue number | 6 |
| State | Published - Jun 1 2002 |
Fingerprint
Keywords
- Animal model
- Cerebrovascular disorder
- Endothelium
- Vascular pharmacotherapy
ASJC Scopus subject areas
- Pharmacology
Cite this
Endothelium-targeted pharmacotherapeutics for the treatment of stroke. / Danton, Gary; Watson, Brant D.; Prado, Ricardo; Dalton Dietrich, W.
In: Current Opinion in Investigational Drugs, Vol. 3, No. 6, 01.06.2002, p. 896-904.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Endothelium-targeted pharmacotherapeutics for the treatment of stroke
AU - Danton, Gary
AU - Watson, Brant D.
AU - Prado, Ricardo
AU - Dalton Dietrich, W.
PY - 2002/6/1
Y1 - 2002/6/1
N2 - The pathophysiology of stroke in humans is much more complex than what is typically studied in animal models. Embolic stroke models are more complex than pure ischemia models, but are more representative of human disease and may be particularly useful in the study of new therapeutic strategies. Vascular damage is a prominent feature of embolic stroke, and may be a useful therapeutic target. Serotonin antagonists, adenosine-regulating agents, free radical scavengers, matrix metalloproteinase inhibitors, and HMG-CoA reductase inhibitors are all potentially valuable agents in treating vascular damage after stroke. These agents facilitate decreased infarction volume, hemorrhage, and improved cerebral blood flow.
AB - The pathophysiology of stroke in humans is much more complex than what is typically studied in animal models. Embolic stroke models are more complex than pure ischemia models, but are more representative of human disease and may be particularly useful in the study of new therapeutic strategies. Vascular damage is a prominent feature of embolic stroke, and may be a useful therapeutic target. Serotonin antagonists, adenosine-regulating agents, free radical scavengers, matrix metalloproteinase inhibitors, and HMG-CoA reductase inhibitors are all potentially valuable agents in treating vascular damage after stroke. These agents facilitate decreased infarction volume, hemorrhage, and improved cerebral blood flow.
KW - Animal model
KW - Cerebrovascular disorder
KW - Endothelium
KW - Vascular pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=0036628395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036628395&partnerID=8YFLogxK
M3 - Article
C2 - 12137409
AN - SCOPUS:0036628395
VL - 3
SP - 896
EP - 904
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 6
ER -